BCM
AZN icon

Blume Capital Management’s AstraZeneca AZN Stock Holding History

Blume Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19
Closed -$2.88K – 326
2024
Q3 		$2.88K Buy
+19
New +$3.07K ﹤0.01% 322
2024
Q1 		– Sell
-25
Closed -$3.37K – 315
2023
Q4 		$3.37K Sell
25
-7
-22% -$910 ﹤0.01% 286
2023
Q3 		$4.27K Hold
32
– – ﹤0.01% 278
2023
Q2 		$4.51K Buy
+32
New +$4.71K ﹤0.01% 283
2019
Q1 		– Sell
-250
Closed -$19K – 224
2018
Q4 		$19K Buy
+250
New +$19.5K 0.01% 164

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Blume Capital Management's AZN Position: Q4 2024 in Review

Blume Capital Management sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 19 shares — an estimated $2.88K sold.

Blume Capital Management first reported a position in AZN in Q4 2018 and held it in 5 quarters. The position peaked at $19K in Q4 2018. 1,220 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

  • Blume Capital Management reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
  • Blume Capital Management sold 19 AstraZeneca shares in Q4 2024, an estimated $2.88K.
  • Blume Capital Management first reported a position in AstraZeneca in Q4 2018 and held it in 5 quarters.
  • Blume Capital Management's AstraZeneca position peaked at $19K in Q4 2018.
  • 1,220 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Blume Capital Management's 13F filing for Q4 2024, filed 10 Feb 2025.